Alexander Monro Ziekenhuis Stichting

Research site

The Netherlands Professor Bronkhorstlaan 10 G 94, 3723 MB Bilthoven, The Netherlands

1 trial recruiting
Breast cancer · Hormone receptor positive HER2 negative breast cancer · Hormone receptor positive breast cancer
Adult patients

About Specializations

Alexander Monro Ziekenhuis Stichting in Bilthoven, The Netherlands specialises in clinical trials of conditions such as Breast cancer, Hormone receptor positive HER2 negative breast cancer, Hormone receptor positive breast cancer, Hormone refractory breast cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Oncology

The medical center is at the forefront of oncology research, with a particular focus on breast cancer. The institution is dedicated to advancing treatment strategies for hormone receptor-positive and HER2-negative metastatic breast cancer.

Endocrine Therapy
CDK 4/6 Inhibition
Progression-Free Survival

Through innovative clinical trials, the center evaluates the efficacy of combining non-steroidal aromatase inhibitors with CDK4/6 inhibitors to enhance patient outcomes. This research is pivotal in refining therapeutic approaches and improving the quality of life for patients with advanced breast cancer.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Professor Bronkhorstlaan 10 G 943723 MB BilthovenThe Netherlands

Open in maps ↗

Recruiting now: 1 trial
Conditions studied: 5

More sites in Bilthoven The Netherlands

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

2 clinical trials

Breast cancer+3

Recruiting

Study on Oxybutynin and Venlafaxine for Reducing Hot Flashes in Women Undergoing Endocrine Therapy After Breast Cancer

Registered drugNo placebo

Study on Oxybutynin and Venlafaxine for Reducing Hot Flashes in Women Undergoing Endocrine Therapy After Breast Cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Anastrozole
Sponsor:Reinier de Graaf Groep

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Two Treatment Sequences of CDK4/6 Inhibitors (Abemaciclib, Palbociclib, or Ribociclib) in Hormone Receptor Positive Advanced Breast Cancer

Registered drugNo placebo

Study Comparing Two Treatment Sequences of CDK4/6 Inhibitors (Abemaciclib, Palbociclib, or Ribociclib) in Hormone Receptor Positive Advanced Breast Cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Abemaciclib
Sponsor:BOOG Study Center B.V.

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites